TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03434106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Study: NCT04459117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NACL 0.9%
Description: In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.
Study: NCT01241903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: frequency and duration
Study: NCT01164449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study: NCT02877784

Intervention type: PROCEDURE
Intervention: Videofluoroscopic swallowing study
Description: Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.

Intervention type: OTHER
Intervention: Functional Oral Intake Scale
Description: The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.

Intervention type: OTHER
Intervention: Eating Assessment Tool-10
Description: The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
Study: NCT01870310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterised renal denervation
Study: NCT03697681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl (normal saline)
Description: The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
Study: NCT02841462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-bursal thermal ablation
Description: A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
Study: NCT02572765

Intervention type: OTHER
Intervention: PET/CT scan
Description: PET/CT scan

Intervention type: OTHER
Intervention: PET/CT scan
Description: PET/CT scan
Study: NCT03332446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold water immersion
Description: 10 min at 12-15°C
Study: NCT03075709

Intervention type: OTHER
Intervention: Clinical Pathway (CPW)
Description: CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.

Intervention type: OTHER
Intervention: Clinical Pathway (CPW)
Description: CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
Study: NCT00364741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: During and 2 hours after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: During and 2 hours after surgery
Study: NCT00627133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: 2 gram iv load, 500mg bid
Study: NCT01500486

Intervention type: DEVICE
Intervention: NordiFlex PenMate™
Description: Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
Study: NCT03899987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study: NCT02391519

Intervention type: PROCEDURE
Intervention: Collection of myometrial, cord blood, and placental tissue samples
Description: We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).

Intervention type: PROCEDURE
Intervention: Collection of myometrial, cord blood, and placental tissue samples
Description: We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Study: NCT02235545

Intervention type: DEVICE
Intervention: St. Jude Medical Optisure Lead
Description: Patients implanted with St. Jude Medical Optisure Lead
Study: NCT02338700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT02338700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT02815644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin/linagliptin FDC
Description: empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
Study: NCT02715986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI
Description: Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
Study: NCT02604914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: Subcutaneous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: Subcutaneous solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCIG
Description: Intrajejunal Gel
Study: NCT03021772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
Study: NCT03434106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes
Study: NCT03979352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: Treatment with empagliflozin 25mg orally once a day
Study: NCT03021772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
Study: NCT02556060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine
Description: Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosing schedule as study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Same dosing schedule as study drug
Study: NCT03979352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: artificial pancreas
Description: Insulin delivery via a closed loop single-hormone artificial pancreas system.
Study: NCT01123395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg intact tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg tablet dissolved in apple juice
Study: NCT03485521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The tracheobronchial aspiration
Description: Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The tracheobronchial aspiration
Description: Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure
Study: NCT00793130

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coltect
Description: Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
Study: NCT03471741

Intervention type: RADIATION
Intervention: IMRT with concomitant boost

Intervention type: RADIATION
Intervention: 3D-RT with sequential boost
Study: NCT02359513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: bulimic patients are treated during 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
Study: NCT00422383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
Study: NCT02508012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immuno monitoring
Description: treatment optimization
Study: NCT00422383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
Study: NCT00169208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m² IV, D1 each cycle during 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 40 mg/m²/day IV , D1 each cycle during 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: 10 mg/m² IV, D2-3-4 each cycle during 4 cycles
Study: NCT03006874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg QD
Description: CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
Study: NCT03979352

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: artificial pancreas
Description: Insulin delivery via a closed loop single-hormone artificial pancreas system.
Study: NCT01992497

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study: NCT04325737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
Study: NCT03006874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg QD
Description: CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
Study: NCT02098278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01108523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP828-101
Study: NCT03219346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care program
Description: Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
Study: NCT00894946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol + IVF
Description: IVF preceded by lipiodol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol + IVF
Description: IVF preceded by lipiodol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF
Description: IVF alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF
Description: IVF alone
Study: NCT04325737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
Study: NCT03669237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different reconstruction methods
Description: Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
Study: NCT02725229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parasternal block
Description: parasternal block and PCA for sternotomy pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS group
Description: TENS and PCA for sternotomy pain
Study: NCT03639337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
Study: NCT00868933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic index dietary intervention program
Description: The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simple lifestyle advice
Description: The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
Study: NCT03935633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator， oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator， oral tablets
Study: NCT01108536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive prosthetic socket
Description: trans tibial socket with actuator zones (inflatable fluid bladders)
Study: NCT03513484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study: NCT00132418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel
Description: Enbrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02725229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: PCA for sternotomy pain
Study: NCT03135938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grading Inferior Oblique Anterior Transposition surgery
Description: in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Inferior Oblique Anterior Transposition surgery
Description: in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
Study: NCT02373644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Thrust Manipulation and DN
Description: HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
Study: NCT04591444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Sealant
Description: Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: 4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.